Milestone® Pharmaceuticals (NASDAQ: MIST) shares plunged sharply by 31.25% in pre-market trading on Friday, July 11, 2025, falling to $1.76. This steep drop comes after the stock closed at $2.56 in the previous session.
Milestone® Pharmaceuticals Inc. (MIST) announced that the FDA has accepted for review the company’s response to the Complete Response Letter for CARDAMYST™ (etripamil) nasal spray, an investigational therapy for treating paroxysmal supraventricular tachycardia (PSVT). The FDA set a new PDUFA target action date of December 13, 2025.
